Patents Assigned to Sumitomo Pharmaceuticals Company
-
Publication number: 20020147204Abstract: A compound of the formula: 1Type: ApplicationFiled: March 26, 2002Publication date: October 10, 2002Applicant: Sumitomo Pharmaceuticals Company, LimitedInventors: Kazuhito Ikeda, Tohru Tatsuno, Hiroki Ogo, Toshio Nishihara, Tatsuya Fujibayashi, Ryu Nagata
-
Patent number: 6458798Abstract: A pyrimidine derivative of the formula (1) or a salt thereof; has an inhibitory activity of production of Th2 type cytokines such as IL-4, IL-5, etc., and is useful as an therapeutic agent for allergic diseases, autoimmune diseases such as systemic lupus erythemathosus, etc., and acquired immunodeficiecy syndrome (AIDS) and so on.Type: GrantFiled: February 27, 2001Date of Patent: October 1, 2002Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Hitoshi Fujita, Fujio Antoku, Norio Fujiwara, Kiyotaka Iwai, Hiroshi Tanaka, Hajime Kawakami
-
Patent number: 6452008Abstract: A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is preferably especially from the standpoint of safety. wherein R1 is hydrogen, alkyl, substituted alkyl, etc.; Y1 is hydrogen, alky, substituted alky, etc.; Y2 and Y3 are indenpently hydrogen, halogen, etc.; and L is alkyl, substituted alkyl, etc.Type: GrantFiled: May 14, 2001Date of Patent: September 17, 2002Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Masami Muraoka, Koji Morishita, Nagisa Aida, Masashi Tanaka, Masatoshi Yuri, Naohito Ohashi
-
Patent number: 6436669Abstract: The present invention provides a novel Semaphorin having neurite-outgrowth inhibition activity or proteins analogous thereto, peptide fragments of, or antibodies against, such proteins, genes encoding such proteins, expression vectors for said genes, transformed cells into which said expression vectors have been introduced, methods for producing a recombinant protein which employ said transformed cells, antisense nucleotides against the above genes, transgenic animals involving insertion or deletion of the above genes, and screening methods for antagonists of the above proteins, all of which are useful mainly in diagnoses, treatments, or studies relating to neurological diseases. The present invention further provides use of such proteins, peptides, antibodies, genes, or antisense nucleotides as pharmaceutical or diagnostic agents or laboratory reagents.Type: GrantFiled: May 14, 1999Date of Patent: August 20, 2002Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Shinobu Inagaki, Tatsuo Furuyama
-
Patent number: 6433019Abstract: The present invention relates to a neurotrophic factor secretagogue, in particular, to a BDNF (brain-derived neurotrophic factor) secretagogue, which comprises as an active ingredient an NO donor. The medicament of the present invention promotes the secretion of neurotrophic factors from mammalian central neural cells. Thus, the medicament of the present invention, i.e., NO donor, is possibly applicable to the treatment of diseases caused by neutrotrophic factors, for example, neurodegenerative diseases, and is expected to exhibit the efficacious effects thereon. Also, the present invention provides a novel medication for neurodegenerative diseases.Type: GrantFiled: July 28, 2000Date of Patent: August 13, 2002Assignee: Sumitomo Pharmaceuticals Company, LimitedInventor: Hiroyuki Nawa
-
Patent number: 6420381Abstract: A compound of the formula (I): wherein Ring A is substituted or unsubstituted pyridine ring, Y is substituted or unsubstituted alkyl, etc., R1 is hydrogen, or substituted or unsubstituted alkyl, etc., R2 is hydrogen or lower alkyl, R3 is lower alkyl, Z is 1) —D1—Q [D1 is direct bond or divalent C1-8 hydrocarbon, etc., Q is hydroxy, carboxyl, etc.], or 2) —D2M—E—W [D2 is direct bond or divalent C1-8 hydrocarbon, etc., M is oxygen, sulfur, etc., E is direct bond or divalent C1-8 hydrocarbon, etc., W is hydroxyl, carboxyl, etc.], or a prodrug thereof, or a pharmaceutically acceptable salt of the same, which exhibits acyl-CoA: cholesterol acyl transferase (ACAT) inhibitory activity, and is useful as an agent for treatment of hyperlipidemia and atherosclerosis.Type: GrantFiled: February 9, 2001Date of Patent: July 16, 2002Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Masami Muraoka, Hitoshi Ban, Naohito Ohashi
-
Patent number: 6384033Abstract: A compound of the formula: wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2; R1 is hydogen atom, optionally substituted alkyl, etc.; R2 and R3 are independently optionally substituted alkyl, etc.; R4 and R5 are independently hydrogen atom or optionally substituted alkyl; R6 is hydrogen atom, hydroxy or alkyl; or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders and the like.Type: GrantFiled: April 27, 2000Date of Patent: May 7, 2002Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Kazuhito Ikeda, Tohru Tatsuno, Hiroki Ogo, Toshio Nishihara, Tatsuya Fujibayashi, Ryu Nagata
-
Patent number: 6376469Abstract: &bgr;-Type crystalline amrubicin hydrochloride having a powder X-ray diffraction pattern having average values of diffraction angle(2&thgr;) and relative intensity as given in the following table: diffraction angle(2&thgr;) relative intensity(%) (average value) (average value) 6.3 100 6.7 56 10.1 44 15.3 36 20.3 56 25.6 37 26.5 61 26.9 52 has excellent thermal stability and is used in production of freeze-dried formulations.Type: GrantFiled: May 24, 2000Date of Patent: April 23, 2002Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Kozo Shimago, Yuko Uenishi
-
Patent number: 6369110Abstract: A compound represented by the general formula (1): wherein each of R1, R2, R3, R4 and R5 is a hydrogen atom, an alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a saturated heterocyclic group, an aromatic group, an acyl group or the like; each of Y1, Y2, Y3 and Y4 is a single bond, —CH2—, —O—, —CO— or the like, provided that at least two of Y1 through Y4 are independently a group other than a single bond; and Z may be absent, or one or more Zs may be present and are independently an alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a saturated heterocyclic group, a halogen atom, a carboxyl group, an alkoxycarbonyl group, an aromatic group, an acyl group or the like, is useful as a therapeutic or prophylactic agent for diseases caused by the acceleration of the sodium/proton exchange transport system.Type: GrantFiled: November 27, 2000Date of Patent: April 9, 2002Assignee: Sumitomo Pharmaceuticals CompanyInventors: Masahumi Kitano, Naohito Ohashi
-
Publication number: 20010051732Abstract: A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is preferably especially from the standpoint of safety.Type: ApplicationFiled: May 14, 2001Publication date: December 13, 2001Applicant: SUMITOMO PHARMACEUTICALS COMPANY, LIMITEDInventors: Masami Muraoka, Koji Morishita, Nagisa Aida, Masashi Tanaka, Masatoshi Yuri, Naohito Ohashi
-
Patent number: 6329381Abstract: The present invention relates to a heterocyclic compound of the following general formula (I): wherein X is sulfur atom, oxygen atom or —NR3— (R3 may form a heterocyclic ring or a substituted heterocyclic ring with R1 via the nitrogen atom), R1 is alkyl group, substituted alkyl group, aryl group, substituted aryl group, heterocyclic group or substituted heterocyclic group, and R2 is hydrogen atom, halogen atom etc.; or its pharmaceutically acceptable salt and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases comprising the compound (I) or its pharmaceutically acceptable salt as active ingredients.Type: GrantFiled: May 26, 2000Date of Patent: December 11, 2001Assignees: Sumitomo Pharmaceuticals Company, Limited, Japan Energy CorporationInventors: Ayumu Kurimoto, Tetsuhiro Ogino, Hajime Kawakami
-
Patent number: 6323330Abstract: Novel proteins C16 and C16N or genes encoding the same; proteins analogous to these novel proteins; partial peptides; antibodies; transgenic animals; a method for screening inhibitors by using these novel proteins; inhibitors obtained by the above screening method; etc. are provided. The novel proteins C16 and C16N or the proteins analogous thereto have the activities of inducing cells to become capable of resorbing hydroxyapatite, maintaining the survival of neurons, inhibiting the proliferation of osteoblasts, and/or promoting the expression of type I collagen in osteoblasts. Thus, the above proteins are applicable to the treatment of various diseases which are curable through expression of these functions.Type: GrantFiled: October 23, 1998Date of Patent: November 27, 2001Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Yasuyuki Ishiduka, Reiko Mochizuki
-
Patent number: 6300500Abstract: A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is preferably especially from the standpoint of safety. wherein R1 is hydrogen, alkyl, substituted alkyl, etc.; Y1 is hydrogen, alky, substituted alky, etc.; Y2 and Y3 are indenpently hydrogen, halogen, etc.; and L is alkyl, substituted alky, etc.Type: GrantFiled: August 25, 2000Date of Patent: October 9, 2001Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Masami Muraoka, Koji Morishita, Nagisa Aida, Masashi Tanaka, Masatoshi Yuri, Naohito Ohashi
-
Patent number: 6271251Abstract: A substituted guanidine derivative represented by the general formula: or a pharmaceutically acceptable acid addition salt thereof, is useful as a therapeutic or prophylactic agent for diseases caused by the acceleration of the sodium/proton (Na+/H+) exchange transport system, for example, hyperpiesia, arrhythmia, angina pectoris, hypercardia, diabetes, organopathies due to ischemia or ischemia re-perfusion, troubles due to cerebral ischemia, diseases caused by cell over-proliferations, and diseases caused by trouble with endothelial cells.Type: GrantFiled: June 29, 1999Date of Patent: August 7, 2001Assignee: Sumitomo Pharmaceuticals Company LimitedInventors: Masahumi Kitano, Naohito Ohashi
-
Patent number: 6248722Abstract: The present invention relates to a medicament comprising a HGF gene. The medicament of the present invention may be topically applied to the target organs so that the effects can be selectively exhibited, resulting in minimizing the side effects of HGF.Type: GrantFiled: June 9, 1998Date of Patent: June 19, 2001Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Ryuichi Morishita, Toshio Ogihara, Toshikazu Nakamura, Tetsuya Tomita, Takahiro Ochi
-
Patent number: 6225283Abstract: This invention provides a therapeutic agent for the treatment of an abnormal eating behavior. The psychotic symptoms characteristic of anorexia nervosa such as apocleisis, intentional vomiting, eating in secret and the like have been treated with a tranquilizer and the like, but the effectiveness was only limited. By administration of a therapeutic agent according to the present invention, i.e., a human growth hormone (hGH) formulation, a will to eat can spontaneously be developed in a patient who previously received a nutrition only passively by means of a forcible nutrition program or a nasal nutrition supply. It is effective especially against the eating disorder in anorexia nervosa attributable possible to an increased central growth hormone releasing factor (GRH)-hGH secretion system.Type: GrantFiled: January 8, 1999Date of Patent: May 1, 2001Assignee: Sumitomo Pharmaceuticals Company, LimitedInventor: Kiyoshi Hashizume
-
Patent number: 6210697Abstract: A medicament containing human growth hormone (hGH), which can prevent or decrease the immunosuppression and the onset of infectious diseases such as pneumonia in a hypothermia treatment that has been recognized to show remarkable effects on the lifesaving and/or the improvement of recovery of a patient with serious cerebral injury, and thereby contributing to the expansion of the range of application and the improvement of lifesaving effect of hypothermia treatment.Type: GrantFiled: April 16, 1999Date of Patent: April 3, 2001Assignee: Sumitomo Pharmaceuticals Company, LimitedInventor: Nariyuki Hayashi
-
Patent number: 6159974Abstract: LDL receptor gene expression promoters containing a 1,2,4-triazine derivative of the formula (I): ##STR1## wherein R.sup.1 is optionally substituted phenyl or heterocycle; R.sup.2 is optionally substituted phenyl, naphthyl, aralkyl, 5- or 6-membered aromatic heterocycle, alkyl, or alkenyl; X is O, S or NR.sup.4 ; R.sup.3 is optionally substituted phenyl, naphthyl, aralkyl, 5- to 6-membered aromatic heterocycle, alkyl, cycloalkyl or alkenyl, provided that when X is NR.sup.4, then it may form an optionally substituted nitrogen-containing heterocycle, or a pharmaceutically acceptable salt thereof, which can increase the expression dose (the amount of mRNA) of LDL receptor gene, and thus increase the amount of LDL receptor, and reduce the serum cholesterol level, and are useful in the treatment of hyperlipidemia.Type: GrantFiled: September 24, 1999Date of Patent: December 12, 2000Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Yoshihide Ueno, Koji Morishita, Masami Muraoka, Naohito Ohashi
-
Patent number: 6153581Abstract: Drug which contains human growth hormones capable of recovering the renal function when administered to a patient who has renal insufficiency but has not yet undergone kidney dialysis. By administrating the drug, the loss of renal function represented by an extreme decrease in creatinine clearance or the reciprocal of blood creatinine level can be prevented and thus it can dispense with the dialytic treatment for patients with renal insufficiency.Type: GrantFiled: March 27, 1998Date of Patent: November 28, 2000Assignee: Sumitomo Pharmaceuticals CompanyInventor: Tsutomu Sanaka
-
Patent number: 6100260Abstract: An isoxazole derivative represented by the formula: ##STR1## or a pharmaceutically acceptable salt thereof useful as a therapeutic drug for auto-immune diseases and inflammatory diseases.Type: GrantFiled: April 20, 1998Date of Patent: August 8, 2000Assignee: Sumitomo Pharmaceutical Company, LimitedInventors: Masashi Nakatsuka, Yoshihide Ueno, Shin-ichiro Okada, Fumio Nishikaku